Genetic Analysis AS

09/26/2025 | Press release | Distributed by Public on 09/26/2025 00:30

Genetic Analysis: Genetic Analysis attends the Biomarkers & Precision Medicine congress in London

Press release from Companies

Publicerat: 2025-09-26 08:30:00

Genetic Analysis AS: Genetic Analysis attends the Biomarkers & Precision Medicine congress in London

OSLO, NORWAY, September 26, 2025: Microbiome DX company Genetic Analysis AS ("GA") announces its attendance at the Biomarkers & Precision Medicine congress in London, 30 September - 01 October 2025. The event offers a chance to gain the latest insights from across the biomarker and precision medicine landscape, while providing valuable networking and partnering opportunities.

Genetic Analysis' Head of Commercial, Kari Furu, will attend the congress. GA will use the event to highlight GA's microbiome testing platform, GA-map®, demonstrating how it can be used in the development of new precision medicine strategies, as well as in the discovery of novel microbiome-based biomarkers. Specifically, Kari will showcase GA's recently launched product, the GA-map® MHI GutHealth, for measurements of antibiotic-induced disruptions of the gut microbiome at the Luminex (a Diasorin company) exhibition place. The GA-map® platform utilizes the unique Luminex xMAP® technology for standardized high-plex microbiome tests, making it readily available for xMAP® users worldwide.

For more information about GA, please contact:
Ronny Hermansen, CEO
E-mail: [email protected]

About Genetic Analysis
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA's vision is to become the leading company for standardized gut microbiome testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in sales, operations, bioinformatics, molecular biology, and bioengineering.

For more information: https://www.genetic-analysis.com

Interested in reading more about GA's products? Please visit ga-map.com

CisionLink
Attending Biomarkers and Presicion Medicine in London
Genetic Analysis AS published this content on September 26, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 26, 2025 at 06:30 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]